The characterization of two distinct classes of hematopoietic stem cells based on CD34 expression and the ability of human bone marrow (BM) cells to differentiate into nonhematopoietic cells introduced new levels of complexity within the stem cell compartment. Here we report the identification and purification of a rare human stem cell population with hematopoietic and hepatic potential based on the expression of a receptor for the complement molecule C1q (C1qRp 
The characterization of two distinct classes of hematopoietic stem cells based on CD34 expression and the ability of human bone marrow (BM) cells to differentiate into nonhematopoietic cells introduced new levels of complexity within the stem cell compartment. Here we report the identification and purification of a rare human stem cell population with hematopoietic and hepatic potential based on the expression of a receptor for the complement molecule C1q (C1qRp). We show that C1qRp is a positive marker of all BM-repopulating stem cells because it is expressed on both CD34 ؊ and CD34 ؉ stem cells from umbilical cord blood and adult BM. In addition, we show that highly purified lineage-negative CD45 ؉ CD38 ؊ CD34 ؉or؊ C1qR p ؉ cells not only have BM-repopulating capacity but also can differentiate into human hepatocytes in vivo.
The identification of human hepatocytes in mouse livers indicates that the NOD͞SCID (nonobese diabetic͞severe combined immunodeficient) mouse model can be a valuable tool to study the differentiation potential of adult human stem cells. These findings may have important scientific and clinical implications in the field of human stem cell biology and transplantation.
R ecently, a class of murine and human hematopoietic stem cells (HSCs) was identified and characterized by its lack of CD34 expression (1) (2) (3) (4) (5) (6) . These studies challenged the dogma that all human repopulating cells express CD34. However, the relationship between human CD34 Ϫ and CD34 ϩ stem cells and the role of CD34 Ϫ stem cells in clinical transplantation remain unclear. Xenograft repopulation assays using fetal sheep (7, 8) and immune-deficient mice (9, 10) were crucial for the identification of human CD34 (5) . Moreover, these cells are also able to repopulate secondary recipients, attesting to the extensive self-renewal potential of the engrafting cells. In the nonobese diabetic͞severe combined immunodeficient (NOD͞ SCID) mouse model, SCID-repopulating cells (SRC) lacking CD34 expression (CD34 neg -SRC) are found in the heterogeneous Lin Ϫ CD34 Ϫ cell fraction at a very low frequency (1 in 125,000 cells; ref. 6). CD34 neg -SRC have the ability to give rise to CD34 ϩ cells in vitro and in vivo, and have different cytokine requirements from CD34 pos -SRC (6, 11, 12) . However, until now, the absence of a positive marker for the identification and isolation of human CD34 neg -SRC has hindered their further characterization and prevented their use in clinical transplantation. Here, we investigated whether C1qR p (13) (14) (15) , the human homologue of the mouse stem cell antigen AA4 (16), could be used as a marker to isolate and characterize human HSCs. AA4 has been recently identified as the antigen recognized by AA4.1 monoclonal antibody used to define murine multipotent hematopoietic precursors that can give rise to the entire spectrum of mature blood cells (16) . AA4 may play a role in the homing of hematopoietic stem͞progenitors to the fetal liver (16 CFC and LTC-IC Assays. Human CFC were assayed in semisolid methylcellulose medium in standard conditions (22) . Long-term culture-initiating cell (LTC-IC) cultures were established on preformed M210B4 stroma layers by using human myeloid long-term culture medium (MyeloCult 5100, StemCell Technologies) according to described methods (23, 24) . Limiting dilutions (Ն3 replicates per dilution) were performed in 96-well plates in which 1,000 -20,000
Ϫ per well, and 10 -2,000
C1qR p Ϫ per well were plated. After 5 weeks in coculture with stroma cells, the content of each well was transferred in methylcellulose medium to reveal CFC activity.
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Abbreviations: BM, bone marrow; CB, cord blood; CFC, colony-forming cells; HSA, hepatocyte-specific antigen; HSC, hematopoietic stem cell; Lin Ϫ , lineage-negative; LTC-IC, long-term culture-initiating cell; NOD͞SCID, nonobese diabetic͞LtSz-scid; SRC, SCIDrepopulating cells.
NOD͞SCID Mouse Transplantation. Eight-week-old sublethally irradiated (375 cGy) NOD͞LtSz-scid (NOD͞SCID) mice were transplanted with purified human cell populations by lateral tail vein injection according to a standard protocol (22) . Mice received alternate-day i.p. injections of human cytokines for the first 10 days posttransplant at the following doses: 10 g of human SCF (PeproTech, Rocky Hill, NJ), 6 g of human IL-3 (PeproTech), and 6 g of human G-CSF (Immunex) per mouse per injection. Mice were killed 8-10 weeks posttransplant.
Analysis of Mouse BM. For each killed mouse, BM was harvested by flushing femurs, tibiae, and iliac crests. Red blood cells were lysed using a 6% ammonium chloride solution and the remaining BM cells were incubated with anti-human monoclonal antibodies (CD45-FITC, CD33-PE, CD19-APC) to determine the level and nature of human engraftment. In some experiments, cells were also incubated with anti-human CD2, CD3, CD4, CD8, CD20, CD34, and CD38. Human engraftment was verified by Southern blot analysis. Genomic DNA was isolated from BM by using a standard extraction protocol (22) and probed with a labeled ␣-satellite probe specific for human chromosome 17 (p17H8) as described (22) . The limit of detection was 0.05% human DNA.
Analysis of Mouse Liver. Livers from transplanted or control (no human cells injected) mice were collected, divided, and processed for dissociation, RNA extraction, or fixation. Liver cell suspensions were treated with ammonium chloride for red blood lysis and immunostained with anti-human CD45 and HLA-ABC (Becton Dickinson). mRNA was extracted and cDNA synthesized according to standard procedures. The cDNA was amplified by PCR using human albumin primers: 5Ј-CATTAGCTGCTGATTTTGTTGAAAG; 3Ј-TGTGCAG-CAT TTTGTGACTCTG. The PCR reactions were completed using the following conditions: denaturation at 94°C for 30 s, annealing at 60°C for 75 s, and extension for 30 s for 40 cycles. A final extension step at 72°C for 10 min was included before samples were cooled at 4°C. For immunohistochemistry, multiple pieces from each liver were fixed in formalin for 24 h, dehydrated, paraffin-embedded, and serially sectioned. Sections were immunostained with anti-human monoclonal antibodies: hepatocyte-specific antigen (HSA, clone OCH15E, Dako) and c-met (clone 8F11, Vector Laboratories). The nonspecific binding of the monoclonal antibodies was assessed for each experiment by using liver section from NOD͞SCID mice that were not transplanted with human cells. Antigens were unmasked using high temperature and a citric acid-based solution (Vector Laboratories). Antigens were revealed using an avidin: biotinylated alkaline phosphatase complex (Vectastain ABC-AP, Vector Laboratories) method and the Vector Red substrate. Sections were counter stained with methyl green (Vector Laboratories).
Results and Discussion
C1qR Is Expressed on Lin ؊ CD38 ؊ CD34 ؉ and Lin ؊ CD38 ؊ CD34 ؊ Cells.
Human C1qR p is expressed on myeloid and endothelial cells (13 (Fig. 1a, gate b) , a population highly enriched for CD34 pos -SRC (22) . Lin
, as determined by forward light scatter (Fig. 1a) . Phenotypic analysis indicates that
ϩ cells do not express stem cell-associated markers such as Thy-1 (CD90) or AC133 (Fig. 1b) . However, some of these cells express the cytokine receptors c-kit (CD117, SCF receptor) or KDR [high-affinity vascular endothelial growth factor (VEGF) receptor], and molecules involved in BM homing, such as CXCR4 (Fig. 1b) Identification of a novel stem cell population: 
CD34
ϩorϪ cells based on C1qR p expression can be used to further enrich for human HSC activity. Various doses of purified cells were transplanted into NOD͞SCID mice by using described protocols (22) , to determine the frequency of SRC within each cell population. Mouse BM was analyzed for the presence of human cells 8 -10 weeks post transplantation. Levels of human cell engraftment in NOD͞SCID mice transplanted with CB (Fig. 2, circles) or BM (Fig. 2, triangles (19) established that some hematopoietic stem cells present in adult BM copurified with stem cells that gave rise to hepatocytes, supporting the new concept that somatic stem cells can change cell fate. However, these reports were based on adult rodent stem cell populations, which may differ from human stem cells in their capacity to give rise to multiple tissues. Nevertheless, the studies by Theise et al. (20) and Alison et al. (21) , based on patients who received BM transplants, indicate that some human adult stem cells present in BM also have the ability to give rise to hepatocytes. Those two studies did not distinguish whether HSCs, mesenchymal stem cells, or hepatic stem cells circulating in the BM were responsible for the observed liver engraftment. Thus, we investigated the potential of human C1qR p ϩ stem cells to differentiate in vivo into hepatocytes.
Livers from NOD͞SCID mice transplanted with
C1qR p ϩ cells were assessed by flow cytometry, immunohistochemistry, and RNA expression analysis. Paraffin-embedded liver sections were immunostained for human HSA and human c-met (hepatocyte growth factor receptor). Liver sections from non-injected NOD͞SCID mice were used as negative controls. Both Lin Ϫ CD38 
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*CFC frequency measured after 2 weeks in culture. † LTC-IC frequency determined after 5 weeks in culture on M210B4 stroma layers followed by 2 weeks in methylcellulose medium.
clusters of human hepatocytes in mouse livers based on their morphology and the presence human-specific positive staining for HSA (Fig. 3a, c-f ) or c-met (Fig. 3a, i-j) . To not solely rely on immunohistochemistry and morphology, we also used reverse transcription-PCR to examine the presence human albumin transcripts in the liver of transplanted mice (Fig. 3b) . We detected human-specific albumin transcripts in mice transplanted with Lin Ϫ CD38 Ϫ CD34 ϩorϪ C1qR p ϩ , confirming the presence of human hepatocytes and demonstrating their ability to express a human hepatocyte-specific gene in the context of mouse liver tissue (Fig. 3b) . Furthermore, using flow cytometry on mouse liver suspensions, we detected a rare population (Յ0.1%) of human (HLA-ABC ϩ ) non-hematopoietic (CD45 Two recent reports (25, 26) have indicated the possibility of fusion in vitro between embryonic stem cells and BM or neuronal stem cells. It is unlikely that the human hepatocytes observed in our study are in fact the product of a fusion between human HSCs and mouse liver cells. Indeed, if such human HSC͞mouse liver hybrids were formed, we would expect the hybrid to have both human HSC markers and mouse liver markers. It seems very unlikely that human HSC͞mouse hepatocyte hybrids would acquire human liver markers, down-regulate CD45 expression, and furthermore be able to express the transcripts for human albumin. It is more plausible, indeed, to speculate that human HSCs circulating into the liver of the mice ''transdifferentiated'' within the mouse liver microenvironment. This last hypothesis is indirectly supported by a recent study of C. Verfaillie's group which indicates that multipotent adult progenitor cells (MAPCs) derived from adult human BM can differentiate in vitro into functional hepatocyte-like cells (27) . In this study, fusion cannot be responsible for the hepatic ''transdifferentiation'' observed. Finally, if human HSCs have the capacity to spontaneously fuse with other cell types in mature organs, recipients of BM transplantation should have polyploid cells in many organs. The organs of sex-mismatched BM recipients have been extensively studied for the presence of donor-derived cells (20, 21, 28) , but there has been no report so far of male-female polyploid cells.
In conclusion, this study identifies C1qR p as a novel human stem cell marker expressed on both CD34 neg and CD34 pos -SRC. The presence of C1qR p on CD34 neg -SRC provides a new means of defining and studying the most primitive population of human BM-repopulating cells. These data also provide the first direct demonstration that a highly purified and phenotypically defined human hematopoietic stem cell population can repopulate the BM and differentiate in vivo into hepatocytes by using the NOD͞SCID mouse model. Although the frequency of human hepatocytes detected was low (0.05-0.1%), this is the first demonstration that a highly purified population of human HSCs can provide hepatic engraftment in absence of overt tissue damage-i.e., sublethal irradiation. Present experiments are attempting to increase the hepatocyte generation by inducing liver damage. Because the purified human HSC populations used in this study may have contained two stem cell fractions responsible for BM repopulation and hepatocyte differentiation, our data gives no indication as to whether hematopoietic and hepatic engraftment can be provided by the same human stem cell. So far, only Krause et al. (29) have provided evidence that a single mouse stem cell can provide multitissue engraftment. Gene-marking͞clonal analysis experiments will be needed in the future to address whether a same human stem cell has the capacity to repopulate the entire blood system and at the same time generate hepatocytes. Despite the lack of a definitive proof of the bipotentiality of Lin
ϩ cells, the use of HSCs for the potential treatment of human liver diseases represents an exciting new therapeutic strategy. HSCs represent a safe and accessible source of human stem cells that can be genetically manipulated and may thus prove to be an ideal vehicle for delivering therapeutic genes to the liver. The NOD͞ SCID xenotransplant model will play an important role in evaluating this potential. Moreover, in light of the recent identification of a single mouse BM-derived stem cell with multiorgan and multilineage engraftment (28) , additional experiments will be required to determine the full developmental capacity of these primitive human C1qR p ϩ populations. In conclusion, our results suggest that C1qR p ϩ cells may become a valuable source of stem cells for both BM repopulation and treatment of liver disease.
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